Has semaglutide transformed treatment of diabetes and obesity in India?
So what is semaglutide and who uses it in India? Semaglutide belongs to the class of drugs called Glucagon-like peptide-1 ...
New guidelines for treatment of Type 2 diabetes from International Diabetes Federation soon
IDF creating new Type 2 diabetes guidelines with global experts, focusing on patient-centered care and global accessibility.
Novo Nordisk A/S (NYSE:NVO) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...
pharmaphorum2d
AstraZeneca raises 2022 guidance, names Demaré as non-exec chair
Meanwhile, the rare disease portfolio acquired along with Alexion grew 6% to $1.8 billion, with a 23% increase for complement C5 inhibitor Ultomiris ... than the overall SGLT2 market in most ...
Hosted on MSN17h
SGLT-2 Inhibitors Beneficial for Patients With Nephrolithiasis
TUESDAY, Nov. 12, 2024 (HealthDay News) -- For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) ...
Endocrinology Advisor1d
GLP-1RA Drugs, SGLT2 Inhibitors Prevent Liver Disease in T2D
GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.
News Medical2d
GLP-1 and SGLT2 inhibitors show promise in preventing recurrent stroke and heart attack
GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...
EurekAlert!2d
GLP-1, SGLT2 medications may lower stroke survivor’s risk of future heart attack, stroke
In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...
Medscape2d
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ...
Medscape5d
The Role of Kidney in Glucose Homeostasis — SGLT2 Inhibitors, a New Approach in Diabetes Treatment
Normally, filtered glucose is about 125 mg/min. Main action of SGLT2 inhibitors is the induction of glucosuria and osmotic diuresis. SGLT2 inhibitors reduce effectively fasting and postprandial ...
pharmaphorum5d
Trulicity helps SGLT-2 patients lower blood sugar
New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed ...
clinicaladvisor.com1d
FDA Panel Votes on Sotagliflozin, an Oral Treatment for Type 1 Diabetes
On the question of whether the benefits of sotagliflozin, an oral dual sodium-glucose co-transporter types 1 and 2 (SGLT1/SGLT2) inhibitor, outweigh the risks in this patient population, the committee ...